152 related articles for article (PubMed ID: 24159154)
61. Carbapenemase-producing Enterobacteriaceae in Irish critical care units: results of a pilot prevalence survey, June 2011.
Burns K; Morris D; Murchan S; Cunney R; Smyth E; Power M; Schaffer K; Collins C; Sheahan A; Cormican M; Fitzpatrick F
J Hosp Infect; 2013 Jan; 83(1):71-3. PubMed ID: 23149057
[TBL] [Abstract][Full Text] [Related]
62. Evaluation of ROSCO Neo-Sensitabs for phenotypic detection and subgrouping of ESBL-, AmpC- and carbapenemase-producing Enterobacteriaceae.
Hansen F; Hammerum AM; Skov RL; Giske CG; Sundsfjord A; Samuelsen O
APMIS; 2012 Sep; 120(9):724-32. PubMed ID: 22882262
[TBL] [Abstract][Full Text] [Related]
63. Comparison of ceftriaxone versus cefotaxime for childhood upper urinary tract infections.
Bakkaloglu A; Saatci U; Soylemezoglu O; Ozen S; Topaloglu R; Besbas N; Saatci I
J Chemother; 1996 Feb; 8(1):59-62. PubMed ID: 8835111
[TBL] [Abstract][Full Text] [Related]
64. Prevalence of antimicrobial resistances in common pathogenic Enterobacteriaceae in Australia, 2004: report from the Australian Group on Antimicrobial Resistance.
Pearson J; Turnidge J; Franklin C; Bell J;
Commun Dis Intell Q Rep; 2007 Mar; 31(1):106-12. PubMed ID: 17503650
[TBL] [Abstract][Full Text] [Related]
65. Prevalence and risk factors for colonisation with extended spectrum beta-lactamase producing enterobacteriacae vis-à-vis usage of antimicrobials.
Sarma JB; Ahmed GU
Indian J Med Microbiol; 2010; 28(3):217-20. PubMed ID: 20644309
[TBL] [Abstract][Full Text] [Related]
66. Occurrence of extended spectrum β-lactamase-producing Enterobacteriaceae among pet dogs and cats: an emerging public health threat outside health care facilities.
Abdel-Moein KA; Samir A
Am J Infect Control; 2014 Jul; 42(7):796-8. PubMed ID: 24792717
[TBL] [Abstract][Full Text] [Related]
67. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae.
Balakrishnan I; Awad-El-Kariem FM; Aali A; Kumari P; Mulla R; Tan B; Brudney D; Ladenheim D; Ghazy A; Khan I; Virgincar N; Iyer S; Carryn S; Van de Velde S
J Antimicrob Chemother; 2011 Nov; 66(11):2628-31. PubMed ID: 21810837
[TBL] [Abstract][Full Text] [Related]
68. Evaluation of a diagnostic flow chart for detection and confirmation of extended spectrum β-lactamases (ESBL) in Enterobacteriaceae.
Polsfuss S; Bloemberg GV; Giger J; Meyer V; Böttger EC; Hombach M
Clin Microbiol Infect; 2012 Dec; 18(12):1194-204. PubMed ID: 22264296
[TBL] [Abstract][Full Text] [Related]
69. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?
Canoui E; Tankovic J; Bige N; Alves M; Offenstadt G
Med Mal Infect; 2014 May; 44(5):235-7. PubMed ID: 24780641
[No Abstract] [Full Text] [Related]
70. High prevalence of the plasmid-mediated quinolone resistance determinant qnrA in multidrug-resistant Enterobacteriaceae from blood cultures in Liverpool, UK.
Corkill JE; Anson JJ; Hart CA
J Antimicrob Chemother; 2005 Dec; 56(6):1115-7. PubMed ID: 16260446
[TBL] [Abstract][Full Text] [Related]
71. Empirical third-generation cephalosporin therapy for adults with community-onset Enterobacteriaceae bacteraemia: Impact of revised CLSI breakpoints.
Hsieh CC; Lee CH; Li MC; Hong MY; Chi CH; Lee CC
Int J Antimicrob Agents; 2016 Apr; 47(4):297-303. PubMed ID: 27005458
[TBL] [Abstract][Full Text] [Related]
72. Molecular characteristics of extended-spectrum β-lactamases in clinical isolates of Enterobacteriaceae from the Philippines.
Kanamori H; Navarro RB; Yano H; Sombrero LT; Capeding MR; Lupisan SP; Olveda RM; Arai K; Kunishima H; Hirakata Y; Kaku M
Acta Trop; 2011; 120(1-2):140-5. PubMed ID: 21820398
[TBL] [Abstract][Full Text] [Related]
73. Molecular epidemiology, resistance profiles and clinical features in clinical plasmid-mediated AmpC-producing Enterobacteriaceae.
Gude MJ; Seral C; Sáenz Y; Cebollada R; González-Domínguez M; Torres C; Castillo FJ
Int J Med Microbiol; 2013 Dec; 303(8):553-7. PubMed ID: 23999104
[TBL] [Abstract][Full Text] [Related]
74. [Evolution of third-generation cephalosporin resistance in Enterobacteriaceae from 2000 to 2008 in a Perpignan hospital].
Mayoral G; Ferreyra M; Eden A; Gueudet P; Miquel C; Lecaillon E
Pathol Biol (Paris); 2010 Feb; 58(1):7-10. PubMed ID: 19854588
[TBL] [Abstract][Full Text] [Related]
75. Treatment of pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in children.
Katsuta T; Shoji K; Watanabe Y; Saitoh A
Pediatr Infect Dis J; 2013 Apr; 32(4):417-9. PubMed ID: 23274920
[TBL] [Abstract][Full Text] [Related]
76. Leveraging stewardship to promote ceftriaxone use in severe infections with low- and no-risk AmpC Enterobacterales.
Hardy ME; Kenney RM; Tibbetts RJ; Shallal AB; Veve MP
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0082623. PubMed ID: 37882541
[TBL] [Abstract][Full Text] [Related]
77. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute.
Kumar MS; Lakshmi V; Rajagopalan R
Indian J Med Microbiol; 2006 Jul; 24(3):208-11. PubMed ID: 16912442
[TBL] [Abstract][Full Text] [Related]
78. Impact of ceftriaxone de-restriction on the occurrence of ESBL-positive bacterial strains and antibiotic consumption.
Skrlin J; Bacic Vrca V; Marusic S; Ciric-Crncec M; Mayer L
J Chemother; 2011 Dec; 23(6):341-4. PubMed ID: 22233817
[TBL] [Abstract][Full Text] [Related]
79. Enterobacter meningitis--treatment complicated by emergence of mutants resistant to cefotaxime.
Ralph ED; Behme RJ
Scand J Infect Dis; 1987; 19(5):577-9. PubMed ID: 3423747
[TBL] [Abstract][Full Text] [Related]
80. Hydrolytic model for cefotaxime and ceftriaxone resistance in beta-lactamase-derepressed Enterobacter cloacae.
Livermore DM; Riddle SJ; Davy KW
J Infect Dis; 1986 Mar; 153(3):619-22. PubMed ID: 3485161
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
